J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25443. [Epub ahead of print]
Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in chronic hepatitis B patients.
Hsu CW1,2, Yeh C3, Yeh CT1,2.
Author information
1
Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
2
Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan.
3
Department of Biology, University of California, Los Angeles, USA.
Abstract
In chronic hepatitis B (CHB) patients, withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From 2008-March to 2016-September, 48 CHB patients who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for > 1 year), were placed on reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full-dose, lifelong treatment is unachievable. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
